Sporadic Amyotrophic Lateral Sclerosis Clinical Trial
— MX-ALS-001Official title:
A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS)
NCT number | NCT01849770 |
Other study ID # | 43708 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2013 |
Est. completion date | August 2014 |
Verified date | September 2021 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of these doses will be compared to see if one dose is better than the other.
Status | Completed |
Enrollment | 75 |
Est. completion date | August 2014 |
Est. primary completion date | August 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Sporadic Amyotrophic Lateral Sclerosis (SALS) diagnosed as possible, laboratory-supported probable, probable, or definite ALS as defined by revised El Escorial criteria. - Age 18 years or older. - Disease duration = 36 months from ALS symptom onset. - Capable of providing informed consent and following trial procedures. - Subjects must not have taken riluzole for at least 30 days or be on a 50 milligrams twice daily dose of riluzole for at least 60 days prior to randomization (riluzole-naïve subjects are permitted in the study). - Subjects must not have taken medication for muscle cramping such as cyclobenzaprine, baclofen, carisoprodol, or methocarbamol, for at least 30 days prior to randomization or be on a stable dose for at least 60 days prior to randomization. - Geographic accessibility to the site. - Women must not become pregnant for the duration of the study and must be willing to use two contraceptive therapies and have a negative pregnancy test throughout the course of the study. - Slow vital capacity (SVC) measure greater than or equal to 50% of predicted for gender, height, and age at the screening visit. - Subjects medically able to undergo lumbar puncture (LP) as determined by the investigator (for example, no bleeding disorder, allergy to local anesthetics, a skin infection at or near the LP site, or evidence of high intracranial pressure). - Must be able to swallow capsules throughout the course of the study, according to Principal Investigator (PI) judgment. - Must have a caregiver assist with dispensing the study drug. Exclusion Criteria: - Invasive ventilator dependence, such as tracheostomy. - Creatinine level greater than 1.5 milligram/deciliter. - Serum glutamic oxaloacetic transaminase or (aspartate transaminase) / serum glutamic pyruvic transaminase (alanine aminotransferase) greater than 3 times the upper limit of normal at screening. - History of known sensitivity or intolerability to mexiletine or lidocaine. - Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia. - Clinically significant conduction abnormalities on electrocardiogram or a known history of cardiac arrhythmia. - Known history of epilepsy. - Known history of congestive heart failure (CHF) or history of myocardial infarction within the past 24 months. - Use of mexiletine for 60 days prior to Baseline Visit. - Exposure to any other experimental agent (off-label use or investigational) including high dose creatine (greater than 10 grams a day) within 30 days prior to Baseline Visit. - Use of amiodarone, flecainide, duloxetine, tizanidine, or clozapine. - Pregnant women or women currently breastfeeding. - Placement of Diaphragm Pacing System (DPS) device less than 60 days prior to Baseline Visit. - Planned DPS device implantation after Baseline Visit. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas |
United States | Penn State Hershey Medical Center | Hershey | Pennsylvania |
United States | University of Iowa | Iowa City | Iowa |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | UCLA, Neuromuscular Research Center | Los Angeles | California |
United States | Washington University Medical School | Saint Louis | Missouri |
United States | University of Washington Medical Center | Seattle | Washington |
United States | SUNY Upstate Medical Center | Syracuse | New York |
United States | University of Massachusetts (Worcester) Memorial Medical Center | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
University of Washington |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score | The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival. | Week 0, Week 2, Week 6, Week 12 (or Early Termination Date), and Week 16 | |
Other | Change in Slow Vital Capacity (SVC) Score | The vital capacity (VC) (percent of predicted normal) will be determined, using the slow VC method. The SVC can be measured using conventional spirometers that have had a calibration check prior to subject testing. A printout from the spirometer of all SVC trials will be retained. | Week 0, Week 6, and Week 12 (or Early Termination Date) | |
Primary | Percentage of Participants That Discontinued Study Drug | Information on adverse effects of mexiletine will be determined at each visit by direct questioning of the subjects, clinical examination, review of concomitant medications, vital signs and laboratory test results. | Screening, Baseline Visit Pre-Dose and Post-Dose, Weeks 2, 6, and 12, and at the Final Safety Visit, if a subject discontinues study drug early. Adverse Events will be assessed via telephone Weeks 1, 10, and 16. | |
Secondary | Trough Plasma Concentration (Cmin) of Mexiletine | Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. | Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6) | |
Secondary | Peak Plasma Concentration (Cmax) of Mexiletine | Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. | Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6) | |
Secondary | Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma. | Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. | Week 6 Visit (up to 6 hours post dose) | |
Secondary | Mean Cerebrospinal Fluid (CSF)/Plasma Ratio | The concentrations of Mexiletine were measured in cerebrospinal fluid (CSF) and plasma. | Week 6 Visit (up to 6 hours post dose) | |
Secondary | Mean Weekly Cramp Frequency | Week 3-12, post titration of study medication | ||
Secondary | Maximal Pain Severity | At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms. Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily. |
Weeks 3-12, post titration of study medication | |
Secondary | Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12 | Week 3-12, post titration of study medication | ||
Secondary | Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12 | Week 3-12, post titration of study medication | ||
Secondary | Mean Pain Severity | At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.
The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms. Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily. |
Weeks 3-12, post titration of study medication | |
Secondary | Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12 | Week 3-12, post titration of study medication |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02781454 -
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT02969759 -
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
|
Phase 0 |